FDA Grants Priority Review For Full Approval Of Calliditas Therapeutics' TARPEYO For Treating IgA Nephropathy
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted priority review for full approval of Calliditas Therapeutics' TARPEYO for treating IgA Nephropathy. This could potentially expedite the drug's approval process.
August 18, 2023 | 8:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics' stock could potentially see a positive impact as the FDA has granted priority review for its drug TARPEYO.
The FDA's priority review status for Calliditas Therapeutics' TARPEYO could expedite the drug's approval process, potentially leading to earlier sales and revenue. This could positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100